drugset / Trial / NCT04866069
Study of a Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Adjuvanted Inactivated Vaccine in Healthy Adults
Phase 1
Terminated
50 enrolled
Osman ERGANIS, PhD, Prof
MonitorCRO · collabThe Scientific and Technological Research Council of Turkey · collabVETAL Inc. · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
This phase I study is designed as double-blinded, randomised, placebo controlled, three-armed study composed of two different dose arms of protective adjuvanted inactivated vaccine against SARS-CoV-2 in dose escalations (first low dose group, followed by high dose group) and placebo arm.
Timeline
- Start
- 2021-04-25
- Primary completion
- 2021-09-05
- Completion
- 2021-09-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elasomeran | Messenger RNA (mRNA) | 10 ug | Subcutaneous |
| Subject | Elasomeran | Messenger RNA (mRNA) | 20 ug | Subcutaneous |